Mechanistic basis of G595R-mediated resistance to entrectinib in TRK kinase: a structural-energetic perspective

Minyu Li1, Xu Jiang2, Tingting Du1

  • 1Department of VIP Clinic, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.

Abstract

Insights

A G595R mutation in tropomyosin receptor kinase (TRK) fusion proteins causes entrectinib resistance by disrupting drug binding. This resistance mechanism involves steric clashes and altered protein dynamics, impacting cancer treatment efficacy.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Computational Chemistry

Background:

  • Tropomyosin receptor kinase (TRK) family proteins are crucial in oncogenic signaling.
  • NTRK gene alterations drive various cancers, making TRK inhibitors like entrectinib effective treatments.
  • Acquired resistance mutations, such as G595R, limit the long-term efficacy of TRK inhibitors.

Purpose of the Study:

  • To investigate the molecular mechanisms by which the G595R mutation confers resistance to entrectinib.
  • To elucidate the structural and dynamic changes induced by the G595R mutation in the TRK ATP-binding pocket.

Main Methods:

  • Utilized molecular dynamics (MD) simulations to model entrectinib binding to wild-type and G595R mutant TRK.
  • Employed MM-GBSA (Molecular Mechanics with Generalized Born Surface Area) calculations for binding free energy analysis.
  • Performed domain cross-correlation analysis to assess inter-domain communication.

Main Results:

  • The G595R mutation introduces steric clashes and disrupts hydrophobic packing in the ATP-binding site, affecting entrectinib interaction.
  • Binding free energy calculations showed a significant increase in resistance due to lost van der Waals forces and hydrogen bonds.
  • Weakened dynamic coupling between the glycine-rich loop and hinge region was observed, compromising inhibitor binding affinity.

Conclusions:

  • The G595R substitution mechanistically explains entrectinib resistance in TRK fusion-positive cancers at atomic resolution.
  • Single-point mutations can induce long-range effects on protein dynamics and allosteric regulation, impacting drug efficacy.
  • Understanding these resistance mechanisms is vital for developing next-generation TRK inhibitors.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...